



CELL AG TECH Signs Agreement with CCRM to Scale-Up its Patent-Pending Cell Manufacturing Process for Cellular Aquaculture

TORONTO, ON, April 18, 2022 - CELL AG TECH, a cellular agriculture company focused on developing, manufacturing and commercializing cell-cultured lean white fish utilizing their patent-pending technology announced today that they have signed an agreement with CCRM to scale-up their cell manufacturing process for cell-based fish products. CCRM is a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies.

In collaboration with CELL AG TECH, CCRM will use its expertise in cell manufacturing to develop a cost-effective and efficient manufacturing process for fish cells in bioreactors.

“We are honored and excited to work with CCRM on this important project. Their experience in cell manufacturing is broad and unique, and their ability to apply principles developed for regenerative medicine to cellular agriculture will efficiently accelerate our product development process,” commented Dr. Valentin Fulga, Co-Founder of CELL AG TECH.

“A collaboration with CCRM aligns well with our development strategy where we focus on our core expertise while benefiting from and leveraging the experience, capabilities and infrastructure of organizations that excel in complementary fields important to cellular agriculture. Working with the best organizations in their respective fields will allow us to efficiently accomplish our goals,” added Josh Pollack, Co-Founder of CELL AG TECH.

“Cellular aquaculture is an emerging and exciting area of research,” said Dr. Michael May, President and CEO of CCRM. “CCRM is happy to support Canadian innovators like CELL AG TECH by providing process development services.”

About CELL AG TECH

CELL AG TECH is one of the few cellular agriculture companies in the world focused on fish, and their mission is to become a global leader in the production of sustainable cell-cultured seafood. Their initial focus is on lean white fish, and their ultimate goal is to develop, manufacture and commercialize cell-cultured fish filets that are price competitive, cruelty-free, sustainable, environmentally friendly, healthy, widely available, and taste great. With their founder’s business and entrepreneurial experience, the scientific expertise of their team, and their network of reputable collaborators, they are well positioned to bring cell-cultured seafood products to the world and to become a key player in the future of seafood. Visit www.cellagtech.com and follow @cellagtech on Facebook, Instagram, Twitter and LinkedIn (www.linkedin.com/company/cellagtech).

About CCRM

CCRM is a global, public-private partnership headquartered in Canada. It receives funding from the Government of Canada, the Province of Ontario and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients with specialized teams, dedicated funding and unique infrastructure. CCRM is the commercialization partner of the University of Toronto’s Medicine by Design. CCRM is hosted by the University of Toronto. Visit us at ccrm.ca.